Compile Data Set for Download or QSAR
Report error Found 40 Enz. Inhib. hit(s) with all data for entry = 2932
TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385552(US10287278, Example 15 | US10287278, Example 14 | ...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385552(US10287278, Example 15 | US10287278, Example 14 | ...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385539(3-(4-Chloro-2-hydroxy-3-methanesulfoximinophenylam...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385546(US10287278, Example 17 | US10287278, Example 16 | ...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385546(US10287278, Example 17 | US10287278, Example 16 | ...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385549(US10287278, Example 11 | US10647706, Example 11)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385548(US10287278, Example 10 | US10647706, Example 10)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385550(US10287278, Example 13 | US10287278, Example 12 | ...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385550(US10287278, Example 13 | US10287278, Example 12 | ...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385545(US10287278, Example 7 | US10647706, Example 7)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385544(US10287278, Example 6 | US10647706, Example 6)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385547(US10287278, Example 9 | US10647706, Example 9)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385546(US10287278, Example 17 | US10287278, Example 16 | ...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385541(US10287278, Example 3 | US10647706, Example 3)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385556(US10287278, Example 19 | US10287278, Example 18 | ...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385540(3-{4-Chloro-2-hydroxy-3-methane[(N-methyl)sulfoxim...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385556(US10287278, Example 19 | US10287278, Example 18 | ...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385543(US10287278, Example 5 | US10647706, Example 5)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385542(US10287278, Example 4 | US10647706, Example 4)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385540(3-{4-Chloro-2-hydroxy-3-methane[(N-methyl)sulfoxim...)
Affinity DataIC50: 20nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385552(US10287278, Example 15 | US10287278, Example 14 | ...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385550(US10287278, Example 13 | US10287278, Example 12 | ...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385546(US10287278, Example 17 | US10287278, Example 16 | ...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385552(US10287278, Example 15 | US10287278, Example 14 | ...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385548(US10287278, Example 10 | US10647706, Example 10)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385547(US10287278, Example 9 | US10647706, Example 9)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385550(US10287278, Example 13 | US10287278, Example 12 | ...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385549(US10287278, Example 11 | US10647706, Example 11)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385544(US10287278, Example 6 | US10647706, Example 6)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385543(US10287278, Example 5 | US10647706, Example 5)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385546(US10287278, Example 17 | US10287278, Example 16 | ...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385545(US10287278, Example 7 | US10647706, Example 7)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385540(3-{4-Chloro-2-hydroxy-3-methane[(N-methyl)sulfoxim...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385556(US10287278, Example 19 | US10287278, Example 18 | ...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385539(3-(4-Chloro-2-hydroxy-3-methanesulfoximinophenylam...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385546(US10287278, Example 17 | US10287278, Example 16 | ...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385542(US10287278, Example 4 | US10647706, Example 4)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385540(3-{4-Chloro-2-hydroxy-3-methane[(N-methyl)sulfoxim...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385541(US10287278, Example 3 | US10647706, Example 3)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM385556(US10287278, Example 19 | US10287278, Example 18 | ...)
Affinity DataIC50: 200nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors is determined on a functional test of β-arrest...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
US Patent